dc.contributor.author | Hoffmann-Vold, Anna-Maria | |
dc.contributor.author | Fretheim, Håvard Halland | |
dc.contributor.author | Halse, Anne-Kristine | |
dc.contributor.author | Seip, Marit | |
dc.contributor.author | Bitter, Helle | |
dc.contributor.author | Wallenius, Marianne | |
dc.contributor.author | Garen, Torhild Oddveig | |
dc.contributor.author | Salberg, Anne | |
dc.contributor.author | Brunborg, Cathrine | |
dc.contributor.author | Midtvedt, Øyvind | |
dc.contributor.author | Lund, May-Brith | |
dc.contributor.author | Aaløkken, Trond M | |
dc.contributor.author | Molberg, Øyvind | |
dc.date.accessioned | 2020-02-19T08:19:35Z | |
dc.date.available | 2020-02-19T08:19:35Z | |
dc.date.created | 2019-11-19T11:59:30Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | American Journal of Respiratory and Critical Care Medicine. 2019, 200 (10), 1258-1266. | nb_NO |
dc.identifier.issn | 1073-449X | |
dc.identifier.uri | http://hdl.handle.net/11250/2642447 | |
dc.description.abstract | Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies. Objectives: Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort. Methods: ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed. Measurements and Main Results: At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80–100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03). Conclusions: The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | American Thoracic Society | nb_NO |
dc.title | Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 1258-1266 | nb_NO |
dc.source.volume | 200 | nb_NO |
dc.source.journal | American Journal of Respiratory and Critical Care Medicine | nb_NO |
dc.source.issue | 10 | nb_NO |
dc.identifier.doi | 10.1164/rccm.201903-0486OC | |
dc.identifier.cristin | 1749330 | |
dc.description.localcode | © 2019. This is the authors' accepted and refereed manuscript to the article. Locked until 15.11.2020 due to copyright restrictions. The final authenticated version is available online at: http://dx.doi.org/10.1164/rccm.201903-0486OC | nb_NO |
cristin.unitcode | 194,65,30,0 | |
cristin.unitcode | 1920,9,0,0 | |
cristin.unitname | Institutt for nevromedisin og bevegelsesvitenskap | |
cristin.unitname | Klinikk for ortopedi, revmatologi og hudsykdommer | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 2 | |